Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Integrin-Targeted Drug Discovery Summit - Uncover the Therapeutics Promise of Integrins

Oxurion CSO, Professor Alan Stitt, PhD. is presenting Targeting RGD-Binding Integrins as an Integrative Therapy for Diabetic Retinopathy & Neovascular Age-Related Macular Degeneration,  on August 18 at 11.10 am.

Follow this link for more information and reserving your spot.

 

Date: 
Tuesday, August 17, 2021 to Thursday, August 19, 2021
Type: 
Conferences & Events